[1]
|
Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 18, 891-975. https://doi.org/10.1002/ejhf.592
|
[2]
|
Patel, R.B., Vaduganathan, M., Shah, S.J., et al. (2017) Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: Insights into Mechanisms and Therapeutics. Pharmacology & Therapeutics, 176, 32-39.
https://doi.org/10.1016/j.pharmthera.2016.10.019
|
[3]
|
Farris, S.D., Moussavi-Haramai, F. and Stempien-Otero, A. (2017) Heart Failure with Preserved Ejection Fraction and Skeletal Muscle Physiology. Heart Failure Reviews, 22, 141-148. https://doi.org/10.1007/s10741-017-9603-x
|
[4]
|
陈伟伟, 高润霖, 刘力生, 等. 《中国心血管病报告2016》概要[J]. 中国循环杂志, 2017, 32(6): 521-530.
|
[5]
|
Lewis, E.F., Claggett, B., Shah, A.M., et al. (2018) Racial Differences in Characteristics and Outcomes of Patients with Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circulation: Heart Failure, 11, e004457. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004457
|
[6]
|
Rossignol, P. and Ferreira, J.P. (2019) Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring! JACC: Heart Failure, 7, 33-35.
https://doi.org/10.1016/j.jchf.2018.11.016
|
[7]
|
Lam, C.S.P., Voors, A.A., De Boer, R.A., et al. (2018) Heart Failure with Preserved Ejection Fraction: From Mechanisms to Therapies. European Heart Journal, 39, 2780-2792. https://doi.org/10.1093/eurheartj/ehy301
|
[8]
|
Bamaiyi, A.J., Woodiwiss, A.J., Peterson, V., et al. (2019) Insulin Resistance Influences the Impact of Hypertension on Left Ventricular Diastolic Dysfunction in a Community Sample. Clinical Cardiology, 42, 305-311.
https://doi.org/10.1002/clc.23145
|
[9]
|
Varga, Z.V., Giricz, Z., Liaudet, L., et al. (2015) Interplay of Oxidative, Nitrosative/Nitrative Stress, Inflammation, Cell Death and Autophagy in Diabetic Cardiomyopathy. Biochimica et Biophysica Acta, 1852, 232-242.
https://doi.org/10.1016/j.bbadis.2014.06.030
|
[10]
|
Zhang, X., Zhang, Z., Yang, Y., et al. (2018) Alogliptin Prevents Diastolic Dysfunction and Preserves Left Ventricular Mitochondrial Function in Diabetic Rabbits. Cardiovascular Diabetology, 17, 160.
https://doi.org/10.1186/s12933-018-0803-z
|
[11]
|
Reddy, Y.N.V., Andersen, M.J., Obokata, M., et al. (2017) Arterial Stiffening with Exercise in Patients with Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 70, 136-148.
https://doi.org/10.1016/j.jacc.2017.05.029
|
[12]
|
Rosenkranz, S., Gibbs, J.S., Wachter, R., et al. (2016) Left Ventricular Heart Failure and Pulmonary Hypertension. European Heart Journal, 37, 942-954. https://doi.org/10.1093/eurheartj/ehv512
|
[13]
|
Gorter, T.M., van Veldhuisen, D.J., Bauersachs, J., et al. (2018) Right Heart Dysfunction and Failure in Heart Failure with Preserved Ejection Fraction: Mechanisms and Management. Position Statement on Behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20, 1637.
https://doi.org/10.1002/ejhf.1029
|
[14]
|
Borlaug, B.A. and Obokata, M. (2017) Is It Time to Recognize a New Phenotype Heart Failure with Preserved Ejection Fraction with Pulmonary Vascular Disease. European Heart Journal, 38, 2874-2878.
https://doi.org/10.1093/eurheartj/ehx184
|
[15]
|
Fayyaz, A.U., Edwards, W.D., Maleszewski, J.J., et al. (2018) Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated with Heart Failure and Preserved or Reduced Ejection Fraction. Circulation, 137, 1796-1810.
https://doi.org/10.1161/CIRCULATIONAHA.117.031608
|
[16]
|
Reddy, Y.N.V. andersen, M.J., Obokata, M., et al. (2017) Arterial Stiffening with Exercise in Patients? With Heart Failure and Preserved? Ejection Fraction. Journal of the American College of Cardiology, 70, 136-148.
https://doi.org/10.1016/j.jacc.2017.05.029
|
[17]
|
Gabriele, G., Schiattarell, A., Francisco, A., et al. (2019) Nitrosative Stress Drives Heart Failure with Preserved Ejection Fraction. Nature, 568, 351-356. https://doi.org/10.1038/s41586-019-1100-z
|
[18]
|
Oren, O. (2017) Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. The American Journal of Medicine, 130, 510-516. https://doi.org/10.1016/j.amjmed.2016.12.031
|
[19]
|
Pieske, B., Tschöpe, C., De Boer, R.A., et al. (2019) How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA-PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 40, 3297-3317.
https://doi.org/10.1093/eurheartj/ehz641
|
[20]
|
廖玉华, 杨杰孚, 张健, 等. 舒张性心力衰竭诊断和治疗专家共识[J]. 临床心血管病杂志, 2020, 36(1): 1-10.
|
[21]
|
Schiattarella, G.G., Tong, D. and Hill, J.A. (2020) Can HFpEF and HFrEF Coexist? Circulation, 141, 709-711.
https://doi.org/10.1161/CIRCULATIONAHA.119.045171
|
[22]
|
Ge, J.B. (2020) Coding Proposal on Phenotyping Heart Failure with Preserved Ejection Fraction: A Practical Tool for Facilitating Etiology-Oriented therapy. Cardiology Journal, 27, 97-98. https://doi.org/10.5603/CJ.2020.0023
|
[23]
|
Pfeffer, M.A., Shah, A.M. and Borlaug, B.A. (2019) Heart Failure with Preserved Ejection Fraction in Perspective. Circulation Research, 124, 1598-1617. https://doi.org/10.1161/CIRCRESAHA.119.313572
|
[24]
|
Kramer, T., Dumitrescu, D., Gerhardt, F., et al. (2019) Therapeutic Potential of Phosphodiesterase Type 5 inhibitors in Heart Failure with Preserved Ejection Fraction and Combined Post- and Precapillary Pulmonary Hypertension. International Journal of Cardiology, 283, 152-158. https://doi.org/10.1016/j.ijcard.2018.12.078
|
[25]
|
Redfield, M., Borlaug, B., Lewis, G., et al. (2012) Phosphodiesterase-5 Inhibition in Diastolic Heart Failure: The RELAX Trial Rationale and Design. Circulation: Heart Failure, 5, 653-659.
https://doi.org/10.1161/CIRCHEARTFAILURE.112.969071
|
[26]
|
Pieske, B., Maggioni, A.P., Lam, C.S.P., et al. (2017) Vericiguat in Patients with Worsening Chronic Heart Failure and Preserved Ejection Fraction: Results of the Soluble Guanylate Cyclase Stimulator in Heart Failure Patients with Preserved EF (Socrates-Preserved) Study. European Heart Journal, 38, 1119-1127.
https://doi.org/10.1093/eurheartj/ehw593
|
[27]
|
Mascolo, A., Urbanek, K., Angelis, A.D., et al. (2020) Angiotensin II and Angiotensin 1-7: Which Is Their Role in Atrial Fibrillation? Heart Failure Reviews, 25, 367-380. https://doi.org/10.1007/s10741-019-09837-7
|
[28]
|
Packer, M. and Kitzman, D.W. (2018) Obesity-Related Heart Failure with a Preserved Ejection Fraction. JACC: Heart Failure, 6, 633-639. https://doi.org/10.1016/j.jchf.2018.01.009
|
[29]
|
El Shear, F. (2019) Novel Paradigms in the Therapeutic Management of Heart Failure with Preserved Ejection Fraction: Clinical Perspectives. American Journal of Cardiovascular Disease, 9, 91-108.
|
[30]
|
Unger, T., Borghi, C., et al. (2020) International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75, 1334-1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
|
[31]
|
Solomon, S.D., Mcmurray, J.V., Anand, I.S., et al. (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 381, 1609-1620.
https://doi.org/10.1056/NEJMoa1908655
|
[32]
|
Graziani, F., Varone, F., Crea, F., Richeldi, L., et al. (2018) Treating Heart Failure with Preserved Ejection Fraction: Learning from Pulmonary Fibrosis. European Journal of Heart Failure, 20, 1385-1391.
https://doi.org/10.1002/ejhf.1286
|
[33]
|
Lopez-De La Mora, D.A., Sanchez-Roque, C., Montoya-Buelna, M., Sanchez-Enriquez, S., Lucano-Landeros, S., Macias-Barragan, J., et al. (2015) Role and New Insights of Pirfenidone in Fibrotic Diseases. International Journal of Medical Sciences, 12, 840-847. https://doi.org/10.7150/ijms.11579
|
[34]
|
Su, M.Y., Lin, L.Y., Tseng, Y.H., Chang, C.C., Wu, C.K., Lin, J.L., et al. (2014) CMR-Verified Diffuse Myocardial Fibrosis Is Associated with Diastolic Dysfunction in HFpEF. JACC: Cardiovascular Imaging, 7, 991-997.
https://doi.org/10.1016/j.jcmg.2014.04.022
|
[35]
|
Costabel, U., Albera, C, Lancaster, L.H., Lin, C.Y., Hormel, P., Hulter, H.N., et al. (2017) An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration, 94, 408-415.
https://doi.org/10.1159/000479976
|
[36]
|
Hasenfu, G., Hayward, C., Burkhoff, D., et al. (2016) A Transcatheter Intracardiac Shunt Device for Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF): A Multicentre, Open-Label, Single-Arm, Phase 1 Trial. The Lancet, 387, 1298-1304. https://doi.org/10.1016/S0140-6736(16)00704-2
|
[37]
|
Zhang, H., Zhang, J., Chen, M.X., et al. (2019) Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients with Combined Pre- and Post-Capillary Pulmonary Hypertension Associated with Left Heart Failure, The PADN-5 Study. JACC: Cardiovascular Interventions, 12, 274-284.
https://doi.org/10.1016/j.jcin.2018.09.021
|
[38]
|
Borlaug, B.A., Carter, R.E., Melenovsky, V., et al. (2017) Percutaneous Pericardial Resection: A Novel Potential Treatment for Heart Failure with Preserved Ejection Fraction. Circulation: Heart Failure, 10, 1-8.
https://doi.org/10.1161/CIRCHEARTFAILURE.116.003612
|
[39]
|
Selvaraj, S., Claggett, B.L., Bohm, M., et al. (2020) Systolic Blood Pressure, Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF. JACC: Cardiovascular Interventions, 75, 1644-1656. https://doi.org/10.1016/S0735-1097(20)31307-3
|
[40]
|
Tsioufis, C., Georgiopoulos, G., Oikonomou, D., et al. (2017) Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots. Current Vascular Pharmacology, 16, 15-22.
https://doi.org/10.2174/1570161115666170414120532
|
[41]
|
Cikes, M., Claggett, B., Shah, A.M., et al. (2018) Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: The TOPCAT Trial. JACC: Heart Failure, 6, 619-724. https://doi.org/10.1016/j.jchf.2018.05.005
|
[42]
|
Lam, C.S., Rienstra, M., Tay, W.T., et al. (2017) Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: Association with Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. JACC: Heart Failure, 5, 92-98. https://doi.org/10.1016/j.jchf.2017.09.001
|
[43]
|
Devore, A.D. and Piccini, J.P. (2018) Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope. JACC: Heart Failure, 6, 698-700. https://doi.org/10.1016/j.jchf.2018.06.010
|
[44]
|
Goyal, P., Almarzooq, Z.I., Cheung, J., et al. (2018) Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: Insights on a Unique Clinical Phenotype from a Nationally Representative United States Cohort. International Journal of Cardiology, 226, 112-118. https://doi.org/10.1016/j.ijcard.2018.02.007
|
[45]
|
Mchugh, K., Devore, A.D., Wu, J.J., et al. (2019) Heart Failure with Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73, 602-611.
https://doi.org/10.1016/j.jacc.2018.11.033
|
[46]
|
Yamamoto, M., Seo, Y., Ishizu, T., et al. (2017) Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients with Diabetes and Heart Failure—Insights from the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry. Circulation Journal, 81, 1662-1669.
https://doi.org/10.1253/circj.CJ-17-0240
|
[47]
|
Miki, I., Atsushi, N., Shin, I., et al. (2019) Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design. Part of Springer Nature 2019. Cardiovascular Drugs and Therapy, 33, 363-370.
https://doi.org/10.1007/s10557-019-06871-3
|
[48]
|
Rozenbaum, Z., Topilsky, Y., Khoury, S., Pereg, D. and Laufer-Perl, M. (2018) Association of Body Mass Index and Diastolic Function in Metabolically Healthy Obese with Preserved Ejection Fraction. International Journal of Cardiology, 277, 147-152. https://doi.org/10.1016/j.ijcard.2018.08.008
|
[49]
|
Huffman, K.M., Koves, T.R., Hubal, M.J., et al. (2014) Metabolite Signatures of Exercise Training in Human Skeletal Muscle Relate to Mitochondrial Remodelling and Cardiometabolic Fitness. Diabetologia, 57, 2282-2295.
https://doi.org/10.1007/s00125-014-3343-4
|
[50]
|
Leggio, M., Fusco, A., Loreti, C., et al. (2019) Effects of Exercise Training in Heart Failure with Preserved Ejection Fraction: An Updated Systematic Literature Review. Heart Failure Reviews, 25, 703-711.
https://doi.org/10.1007/s10741-019-09841-x
|
[51]
|
Lopes, C.P., Danzmann, L.C., Moraes, R.S., et al. (2018) Yoga and Breathing Technique Training in Patients with Heart Failure and Preserved Ejection Fraction: Study Protocol for a Randomized Clinical Trial. Trials, 19, 405.
https://doi.org/10.1186/s13063-018-2802-5
|